1887

Chapter 39 : Detection of Anticytokine Autoantibodies and Clinical Applications

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Detection of Anticytokine Autoantibodies and Clinical Applications, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH39-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH39-2.gif

Abstract:

Anticytokine autoantibodies are an emerging mechanism of disease pathogenesis that have been shown to elicit a broad range of clinical phenotypes. Some anticytokine autoantibodies can lead to immune susceptibility, with examples including nontuberculous mycobacteria, salmonellae, or fungi due to autoantibodies against gamma interferon (IFN-γ) (1); staphylococcal infection due to anti-interleukin-6 (IL-6) autoantibodies (2); infection due to anti-IL-12p70 autoantibodies (3); chronic mucocutaneous candidiasis due to anti-IL-17 and anti-IL-22 autoantibodies (4, 5); and cryptococcal meningitis (6) or infection due to anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies (7). Other diseases in which immunodeficiency is not the primary presentation include the severe lung disease pulmonary alveolar proteinosis (PAP) caused by anti-GM-CSF autoantibodies; pure red cell aplasia (8); pure red-cell aplasia due to antierythropoietin autoantibodies (9); and severe osteoporosis associated with antiosteoprotegerin autoantibodies (10). For other anticytokine autoantibodies, such as anti-IFN-α autoantibodies detected in thymoma or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, their biological effect is not immediately apparent (11). Diagnosis has important implications for management because therapies can be used to directly target the underlying mechanism, i.e., a neutralizing antibody, and not just their ultimate clinical consequences, with approaches such as B-cell depletion (12–14) or receptor agonists (15).

Citation: Browne S. 2016. Detection of Anticytokine Autoantibodies and Clinical Applications, p 365-372. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch39
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Summary of anticytokine autoantibody detection assays. LIPS, luciferase immunoprecipitation system; PE, phycoerythrin; RIA, radioimmunoassay.

Citation: Browne S. 2016. Detection of Anticytokine Autoantibodies and Clinical Applications, p 365-372. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch39
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch39
1. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, Hsu AP, Patel SY, Olivier KN, Lulitanond V, Mootsikapun P, Anunnatsiri S, Angkasekwinai N, Sathapatayavongs B, Hsueh PR, Shieh CC, Brown MR, Thongnoppakhun W, Claypool R, Sampaio EP, Thepthai C, Waywa D, Dacombe C, Reizes Y, Zelazny AM, Saleeb P, Rosen LB, Mo A, Iadarola M, Holland SM. 2012. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 367:725734.[CrossRef].[PubMed]
2. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, Mamani-Matsuda M, Jouanguy E, Gendrel D, Casanova JL. 2008. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180:647654.[PubMed].[CrossRef]
3. Sim BT, Browne SK, Vigliani M, Zachary D, Rosen L, Holland SM, Opal SM. 2013. Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies. J Clin Immunol 33:10571061.[CrossRef].[PubMed]
4. Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachée-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougnères PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207:291297.[CrossRef].[PubMed]
5. Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207:299308.[CrossRef].[PubMed]
6. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, Suputtamongkol Y, Bennett JE, Pyrgos V, Williamson PR, Ding L, Holland SM, Browne SK. 2013. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 190:39593966.[CrossRef].[PubMed]
7. Rosen LB, Pereira NR, Figueirdo C, Fiske LC, Ressner RA, Hong JC, Gregg KS, Henry TL, Pak KJ, Baumgarten KL, Seoane L, Garcia-Diaz J, Olivier KN, Zelazny AM, Holland SM, Browne SK. 2015. Nocardia-induced GM-CSF is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis NEW. Clin Infect Dis 60:10171025.[CrossRef].[PubMed]
8. Carey B, Trapnell BC. 2010. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 135:223235.[CrossRef].[PubMed]
9. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. 1996. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334:630633.[CrossRef].[PubMed]
10. Riches PL, McRorie E, Fraser WD, Determann C, van't Hof R, Ralston SH. 2009. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 361:14591465.[CrossRef].[PubMed]
11. Browne SK. 2014. Anticytokine autoantibody-associated immunodeficiency. Annu Rev Immunol 32:635657.[CrossRef].[PubMed]
12. Borie R, Debray MP, Laine C, Aubier M, Crestani B. 2009. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 33:15031506.[CrossRef].[PubMed]
13. Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, Pancholi MJ, Yang LM, Priel DL, Uzel G, Freeman AF, Hayes CE, Baxter R, Cohen SH, Holland SM. 2012. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 119:39333939.[CrossRef].[PubMed]
14. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ. 2011. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 38:13611367.[CrossRef].[PubMed]
15. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. 2009. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:18481855.[CrossRef].[PubMed]
16. Rosen SH, Castleman B, Liebow AA. 1958. Pulmonary alveolar proteinosis. N Engl J Med 258:11231142.[CrossRef].[PubMed]
17. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, Nakata K. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190:875880.[PubMed].[CrossRef]
18. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. 1999. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett 442:246250.[PubMed].[CrossRef]
19. Dranoff G , et al 1994. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713716.[PubMed].[CrossRef]
20. Robb L, Drinkwater CC, Metcalf D, Li R, Köntgen F, Nicola NA, Begley CG. 1995. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci USA 92:95659569.[PubMed].[CrossRef]
21. Watanabe M, Uchida K, Nakagaki K, Trapnell BC, Nakata K. 2010. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev 21:263273.[CrossRef].[PubMed]
22. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. 2004. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104:35983602.[CrossRef].[PubMed]
23. Höflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, Döcke WD, Grütz G, Meisel C, Halle E, Göbel UB, Volk HD, Suttorp N. 2004. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103:673675.[CrossRef]
24. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK. 2012. Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol 32:238245.[CrossRef].[PubMed]
25. Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, Kristosturyan E, Rajan A, Ding L, Ching KH, Berman A, Oliveira JB, Hsu AP, Klimavicz CM, Iadarola MJ, Holland SM. 2010. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 116:48484858.[CrossRef].[PubMed]
26. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. 2009. Antibody profiling by luciferase immunoprecipitation systems (LIPS). J Vis Exp 32:1549. doi:10.3791/1549[CrossRef].[PubMed] http://dx.doi.org/doi:10.3791/1549
27. Oftedal BE, Wolff AS, Bratland E, Kämpe O, Perheentupa J, Myhre AG, Meager A, Purushothaman R, Ten S, Husebye ES. 2008. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 129:163169.[CrossRef].[PubMed]
28. de Lemos Rieper C, Galle P, Svenson M, Pedersen BK, Hansen MB. 2009. Preparation and validation of radio iodinated recombinant human IL-10 for the measurement of natural human antibodies against IL-10. J Immunol Methods 350:4653.[CrossRef].[PubMed]
29. Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, Martyak LA, Kubak B, Holland SM. 2005. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 175:47694776.[PubMed].[CrossRef]
30. Price JV, Haddon DJ, Kemmer D, Delepine G, Mandelbaum G, Jarrell JA, Gupta R, Balboni I, Chakravarty EF, Sokolove J, Shum AK, Anderson MS, Cheng MH, Robinson WH, Browne SK, Holland SM, Baechler EC, Utz PJ. 2013. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest 123:51355145.
31. Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, Kagamu H, Yoshizawa H, Keicho N, Goto H, Nakata K. 2007. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 581:20172021.[CrossRef].[PubMed]
32. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, Nicol M, Schölvinck E, Relman D, Waddell S, Langford P, Sheehan B, Semple L, Wilkinson KA, Wilkinson RJ, Ress S, Hibberd M, Levin M. 2005. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 115:24802488.[CrossRef].[PubMed]
33. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469475.[CrossRef].[PubMed]
34. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hanaoka K, Seymour JF, Schoch OD, Doyle I, Inoue Y, Sakatani M, Kudoh S, Azuma A, Nukiwa T, Tomita T, Katagiri M, Fujita A, Kurashima A, Kanegasaki S, Nakata K. 2000. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 162:658662.[CrossRef].[PubMed]
35. Nei T, Urano S, Itoh Y, Kitamura N, Hashimoto A, Tanaka T, Motoi N, Kaneko C, Tazawa R, Nakagaki K, Arai T, Inoue Y, Nakata K. 2013. Light chain (κ/λ) ratio of GM-CSF autoantibodies is associated with disease severity in autoimmune pulmonary alveolar proteinosis. Clin Immunol 149:357364.[CrossRef].[PubMed]
36. Bhol K, Mohimen A, Ahmed AR. 1994. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 189(Suppl 1):8589.[PubMed].[CrossRef]
37. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. 1995. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 92:52395243.[PubMed].[CrossRef]
38. Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Ishii H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Akira M, Ichiwata T, Tatsumi K, Yamaguchi E, Nakata K. 2013. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 145:729737.
39. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K. 2010. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 181:13451354.[CrossRef].[PubMed]
40. Courtney LP, Phelps JL, Karavodin LM. 1994. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology 28:223232.[PubMed].[CrossRef]
41. Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa H, Ando M. 1999. Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 14:383389.[PubMed]
42. Schoch OD, Schanz U, Koller M, Nakata K, Seymour JF, Russi EW, Boehler A. 2002. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 57:277280.[PubMed].[CrossRef]
43. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557567.[PubMed].[CrossRef]
44. Andersen BR, Ecklund RE, Kellow WF. 1960. Pulmonary alveolar proteinosis with systemic nocardiosis. A case report. JAMA 174:2831.[PubMed].[CrossRef]
45. Andriole VT, Ballas M, Wilson GL. 1964. The association of nocardiosis and pulmonary alveolar proteinosis: a case study. Ann Intern Med 60:266275.[PubMed].[CrossRef]
46. Burbank B, Morrione TG, Cutler SS. 1960. Pulmonary alveolar proteinosis and nocardiosis. Am J Med 28:10021007.[PubMed].[CrossRef]
47. Carlsen ET, Hill RB Jr, Rowlands DT Jr. 1964. Nocardiosis and Pulmonary Alveolar Proteinosis. Ann Intern Med 60:275281.[PubMed].[CrossRef]
48. Clague HW, Harth M, Hellyer D, Morgan WK. 1982. Septic arthritis due to Nocardia asteroides in association with pulmonary alveolar proteinosis. J Rheumatol 9:469472.[PubMed]
49. Fried J, Hinthorn D, Ralstin J, Gerjarusak P, Liu C. 1988. Cure of brain abscess caused by Nocardia asteroides resistant to multiple antibiotics. South Med J 81:412413.[PubMed].[CrossRef]
50. Oerlemans WG, Jansen EN, Prevo RL, Eijsvogel MM. 1998. Primary cerebellar nocardiosis and alveolar proteinosis. Acta Neurol Scand 97:138141.[PubMed]
51. Raich RA, Casey F, Hall WH. 1961. Pulmonary and cutaneous nocardiosis. The significance of the laboratory isolation of Nocardia. Am Rev Respir Dis 83:505509.[CrossRef].[PubMed]
52. Taleghani-Far M, Barber JB, Sampson C, Harden KA. 1964. Cerebral Nocardiosis and Alveolar Proteinosis. Am Rev Respir Dis 89:561565.[CrossRef].[PubMed]
53. Walker DA, McMahon SM. 1986. Pulmonary alveolar proteinosis complicated by cerebral abscess: report of a case. J Am Osteopath Assoc 86:447450.[PubMed]
54. Wongthim S, Charoenlap P, Udompanich V, Punthumchinda K, Suwanagool P. 1991. Pulmonary nocardiosis in Chulalongkorn Hospital. J Med Assoc Thai 74:271277.[PubMed]
55. Björkholm B, Elgefors B. 1986. Cerebellar aspergilloma. Scand J Infect Dis 18:375378.[CrossRef]
56. Jones CC. 1960. Pulmonary alveolar proteinosis with unusual complicating infections; a report of two cases. Am J Med 29:713722.[PubMed].[CrossRef]
57. Hartung M, Salfelder K. 1975. Pulmonary alveolar proteinosis and histoplasmosis: report of three cases. Virchows Arch A Pathol Anat Histol 368:281287.[PubMed].[CrossRef]
58. Al-Muhsen S, Casanova JL. 2008. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 122:10431051, quiz 1052–1053.[CrossRef].[PubMed]
59. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:6568.[CrossRef].[PubMed]
60. Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, Shirai T, Sugihara T, Hirata S, Kubota T, Harigai M, Miyasaka N. 2013. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann Rheum Dis 72:11001102.[CrossRef].[PubMed]
61. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B. 2007. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357:16081619.[CrossRef].[PubMed]
62. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. 2002. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:21192127.[PubMed].[CrossRef]

Tables

Generic image for table
TABLE 1

Anticytokine autoantibody-associated syndromes

Citation: Browne S. 2016. Detection of Anticytokine Autoantibodies and Clinical Applications, p 365-372. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch39

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error